Introduction
. Upon activation, NK cells kill their targets by the release of perforin and granzymes or through ligation of death receptors [7] .
Such receptors belong to the TNF-receptor superfamily and include Fas (CD95) and Tumor Necrosis Factor-Related Apoptosis-Inducing ligand (TRAIL) receptors. We have previously demonstrated that peripheral blood NK cells express low levels of TRAIL and are unable to kill TRAIL-sensitive tumors [8] .
Zoledronic acid (ZA) is a bisphosphonate that is used to prevent the loss of bone mass and to lower the risk of skeletal complication in patients with bone metastasis [9] . ZA has also been shown to play a role in activation of gamma-delta T cells in an antigen-dependent manner [10] . Furthermore, treatment with ZA and interleukin-2 (IL-2) results in increased serum levels of TRAIL in patients with prostate cancer [11] . In these patients, high serum levels of TRAIL correlated with improved prognosis. Although ZA has been shown to up-regulate NKG2D expression on NK cells in vitro [12] , it has not been studied whether ZA treatment can augment the expression of TRAIL on human NK cells. 
Results

Treatment with ZA induces changes in phenotype of NK cells
NK cells were isolated from healthy donors and co-cultured with irradiated PBMC and IL-2 with (ZA-primed) or without ZA (unprimed). Following exposure to ZA at concentrations ranging from 1 to 10µM, surface expression of TRAIL was up-regulated compared to NK cells not treated with ZA. However, no changes in surface expression of NKG2D, DNAM-1, FasL, perforin, granzymeB, NKp30, or NKp46 were observed. A minor up-regulation in expression of CD69 and NKp44 was detected on NK cells following exposure to ZA ( Figure   1A ). In contrast, when purified NK cells were treated with ZA in absence of feeder cells, no changes in TRAIL expression were observed (Supplemental Figure 1A) , suggesting a requirement for PBMC feeder cells to be present during culturing to induce up-regulation of TRAIL on NK cells.
ZA up-regulates TRAIL expression on NK cells indirectly via monocytes
To determine what cells within the PBMC population were responsible for the increased TRAIL expression on NK cells following treatment with ZA; experiments using different feeder cells were performed. In experiments where NK cells were co-cultured with monocytes, but not T or B cells, treatment with ZA resulted in a significant up-regulation of TRAIL (monocytes, p=0.01; T cells, p=0.1, B cells, p=0.4) (Supplemental Figure 1B) . In contrast, no change in NKG2D expression on NK cells was observed in presence or absence of ZA upon co-culture with monocytes (Supplemental Figure 1C) . The fold change in TRAIL expression following treatment with ZA was higher when NK cells were co-cultured with purified monocytes (3.5-fold, p=0.02) compared to PBMC (1.2-fold, p=0.04) ( Figure 1B ). In addition, following co-culture with purified monocytes, ZA induced a significantly higher expression of TRAIL on NK cells compared to when co-cultured with PBMC feeders (p=0.0005). Moreover, production of soluble TRAIL, but not soluble Fas ligand, was significantly (p=0.02) increased in ZA-primed but not unprimed NK cells ( Figure 1C ).
ZA treatment augments TRAIL-mediated antitumor effects of NK cells
To investigate whether the increase in TRAIL expression on NK cells after exposure to ZA would result in augmented TRAIL-mediated killing; J82 cells were treated with the proteasome inhibitor b-AP15 and used as target. Indeed, ZA-primed NK cells displayed an 
ZA-treated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFNγ
To investigate whether the mechanism of NK cell activation was dependent on cell-contact, ZA was added to transwell cultures of NK cells and monocytes. When added to transwell cultures, ZA still induced an up-regulation of TRAIL expression on NK cells ( Figure 4A ). We examined the supernatant of untreated and ZA-treated monocytes for changes in cytokine production in a multiplex Luminex assay. Several cytokines including; IL-15, MIP-1α, MIP-1β, and IFNγ was detected at higher levels in supernatant of ZA-treated monocytes compared to untreated monocytes. The most pronounced effect was observed in levels of IFNγ with a fold change of 72 between untreated and ZA-treated monocytes. Fold-change between untreated and ZA-treated monocytes in production of IL-15, MIP-1α, and MIP-1β was 1.95, 2.7, and 3.6 respectively. The increased levels of IFNγ were confirmed by ELISA where ZAtreated monocytes produced 60.5-fold more IFNγ compared to untreated monocytes ( Figure   4B ). 
Discussion
Here we show that treatment with ZA increases IFNγ production by monocytes resulting in up-regulation of TRAIL expression on human NK cells. These ZA-primed NK cells displayed an increased ability to kill TRAIL-sensitive tumors in vitro and in vivo. The effects of ZA on hematopoietic cells have previously been investigated. Upon treatment of PBMC with ZA and IL-2, a selective expansion of γδ−T cells has previously been reported [13] . Such γδ−T cells express higher intracellular levels of TRAIL and secrete higher levels of soluble TRAIL [11] .
Recently, Maniar et al. showed an increased expression of the activating receptor NKG2D on human NK cells following co-culture with ZA-treated γδ−T cells [12] . Furthermore, ZA has been shown to activate human NK cells and cytokine-induced killer cells (CIK) in a dendritic cell (DC)-dependent manner. ZA-treated DC-stimulated NK cells to produce higher levels of IFNγ [14] and increased NKG2D expression and anti-tumor cytotoxicity of CIK cells [15] .
However, cell-cell contact was required to induce NK cell activation by ZA-treated γδ−T cells [12] . In agreement with these studies, we found no change in NK cell activity or phenotype when purified NK cells were treated with IL-2 and ZA, confirming that accessory cells need to be present for an efficient activation of NK cells following exposure to ZA. However, in the presence of PBMC, a significant up-regulation of TRAIL expression was observed. [18] . Two separate studies demonstrated that TRAIL and IFNγ cooperate in anti-tumor effects in vivo [19, 20] .
Upon engagement of the T cell receptor, triggering of the TRAIL signaling pathway result in an augmented proliferation and IFNγ production in antigen specific T cells [21] . Furthermore, a recent study in bisphosphonate-naive postmenopausal women with low bone mass showed elevated serum levels of IFNγ after a single infusion of ZA [22] . We further show that direct treatment of purified NK cells with recombinant IFNγ resulted in an increased TRAIL expression on NK cells. Taken together, our in vitro findings provide a novel mechanism of TRAIL regulation in human NK cells.
Purified monocytes cultured in ZA alone produced higher levels of IFNγ compared to untreated monocytes. However, in presence of both IL-2 and ZA, a much higher production of IFNγ was observed. ZA treatment resulted in higher expression of IL-2Rα and IL-2Rβ transcripts in monocytes compared to untreated monocytes suggesting that ZA treated monocytes may respond stronger to IL-2 stimulation (data not shown). Indeed, monocytes treated with ZA and IL-2 displayed an increased phosphorylation of p38 compared to monocytes treated with either IL-2 or ZA alone (data not shown). Moreover, SOCS3
inhibition by ZA [23, 24] resulting in enhanced STAT1/3 signaling may contribute to increased IFNγ production when IL-2 was added to cultures.
It is well known that isopentenyl pyrophosphate (IPP) accumulates in monocytes when treated with ZA [25] . Monocytes that accumulate IPP become antigen-presenting cells and stimulate gamma-delta T cells in peripheral blood. We found that IFNγ production by monocytes was not affected by statins (Simvastatin), that act upstream of IPP production (data not shown).
Furthermore, treatment of monocytes with pamidronate, that like ZA acts downstream of IPP production, resulted in an increased production of IFNγ. However, production of IFNγ was consistently higher following treatment with ZA.
Although TRAIL was significantly up-regulated on ZA-primed NK cells, we were not able to detect any changes in expression of NKG2D either in presence or absence of anti-IFNγ (Supplemental Figure 1C) and confirm previous reports. Neither did we observe any differences in cytotoxicity against tumors cells between ZA-primed nor unprimed NK cells in presence of neutralizing antibodies to NKG2D. In the study by Maniar, the increased NKG2D expression was dependent on 4-1BB ligand interaction on gamma-delta T cells following treatment with ZA. Su et al observed increased NKG2D expression following co-culture with DC and treatment with ZA. Both gamma-delta T cells and DC express high levels of 4-1BB ligand whereas monocytes typically express low levels of 4-1BB ligand [12, 26] . Thus, low expression of 4-1BB ligand expression on monocytes could possibly explain why no change in NKG2D expression was observed in our experiments. Secondly, differences in culture conditions may explain why no change in NKG2D expression was detected. In our experimental system NKG2D was expressed at high levels following seven-day culture of IL- When tumor-bearing mice were treated with the proteasome inhibitor b-AP15 followed by adoptive infusion of ZA-primed, but not unprimed NK cells, a significant delay in tumor progression was observed (p=0.015). In addition, a significant survival advantage (p=0.03) was observed in mice treated with ZA-primed NK cells, compared to mice treated with unprimed NK cells.
In conclusion, we show that ZA and IL-2-treated monocytes augment TRAIL-mediated cytotoxicity by human NK cells. We further identify IFNγ as the main factor responsible for the increased TRAIL expression on human NK cells. In a recent randomized phase III study, adjuvant therapy with ZA showed no clinical benefit in patients with breast cancer [29] . In contrast, Dieli et al showed that treatment with ZA in combination with IL-2 resulted in sustained serum levels of TRAIL, which correlated with improved clinical outcome in patients with hormone-refractory prostate cancer [30] . Although we used the J82 cell line as a model cell line, several other tumor cell lines of different origin including breast cancer, prostate cancer, and melanoma also display increased susceptibility to ZA-primed, but not unprimed NK cells.
Our findings suggest a new strategy to augment NK cell anti-tumor activity by ex vivo exposure to ZA and IL-2, and infusion of such NK cells could potentially result in improved clinical outcome in patients with cancer. feeder) in X-VIVO 20 media (Lonza, Verviers, Belgium) supplemented with 5% heat inactivated human AB serum (Karolinska Hospital, Sweden) for eight days. ZA (Novartis Pharma GmbH, Nurnberg, Germany) was added to cultures (ZA-primed) on days 0, 4 and 7 at 10μM and IL-2 (Novartis pharma GmbH, Nurnberg, Germany) was added on days 0 and 4 at 500U/ml. NK cells were analyzed for proliferation, apoptosis and expression of cell surface markers on day 7. NK cell-mediated tumor cytotoxicity against J82 (bladder cancer, ATCC), PC3 (prostate cancer, ATCC), MCF7 (breast cancer, ATCC), EST025 (melanoma, IPD -ESTDAB), was analyzed on day 8-11. STR Identifier (Applied Biosystems, UK) was used to verify the origin of the J82, MCF7 and EST025 cell lines. All cell lines were maintained in RPMI1640 media with 10% fetal calf serum (Invitrogen, Eugene, Oregon, USA), 50U/ml penicillin, and 50mg/ml streptomycin (Invitrogen). Where indicated, 500pg/ml IFNγ (Peprotech, NJ, USA) was added to NK cells every 2 days for 7 days. (10ug/ml), NKp44 (10ug/ml), FasL (2.5ug/ml) (Biolegend). Concanamycin A (CMA, 100nM, Sigma, Schnelldorf, Germany) was added to cytotoxicity assays to degrade perforin.
Materials and Methods
Cells and reagents
Human
Transwell assay
Transwell assays were performed to determine whether ZA-treated monocytes could upregulate TRAIL expression on NK cells in absence of cell contact. Purified NK (3x10 5 ) cells were plated in 1ml in the lower chamber and monocytes (2x10 6 ) were added to the upper insert (0.4µm pore size) (Corning, NY, USA) in 200μl. Cell cultures were treated with ZA and IL-2 as above. Alternatively, monocytes were cultured in 24 well-plates treated with IL-2 and ZA as above and 500µl supernatant was transferred daily to pure NK cells. Where indicated, monocytes were treated with neutralizing anti-IFNγ antibodies (0.3ug/ml) (R&D systems, Minneapolis, USA) once every day for 7 days prior to transfer to purified NK cells.
Alternatively co-cultures of NK cells and monocytes were treated with neutralizing anti-IFNγ antibodies (0.3ug/ml).
In vivo xenograft study
The animal study (N42/10) was approved by the ethical review board at Karolinska Institutet.
SCID/Beige mice were purchased from Charles River (Sulzfeld, Germany) and bred at the 
Statistical analysis
The in vitro data were analyzed by paired or unpaired t-test and in vivo data were analyzed using unpaired t-test, two-way ANOVA and Log-rank (Mantel-Cox) test. p-values below 0.05
were considered statistically significant between treatment groups. 
